"An investigation of the nature of plasminogen activator inhibitor type" by Justin A. Powers

Date Approved

2019

Degree Type

Open Access Senior Honors Thesis

Department or School

Chemistry

First Advisor

Cory Emal

Second Advisor

Hedeel Evans

Third Advisor

Deborah Heyl-Clegg

Abstract

Plasminogen activator inhibitor type-I (PAI-I ) is a serpin superfamily member protein that acts as the major inhibitor of tissue-type plasminogen activator (tPA) and urokinase-type plasminogen activator (uPA). At physiological levels, PAI-I plays an active role in regulating fibrinolysis, the process of normal blood clot degradation. Pathological levels of PAI-I have been linked to multiple health ailments: fibrosis, heart disease, cancer, and obesity. In recent years, PAI-1 has been the subject of targeted drug design. In this study, we identified a class of polyphenol compounds as the most capable of maintaining its inhibitory efficiency against vitronectin bound PAI-I in buffer and plasma. Additionally, a previously reported class of biphenyl amide PAI-I inhibitors was structurally probed to determine the pharmacophore. We provide evidence supporting the anti-PAI-I pharmacophore as the carboxylic acid moiety, observing modifications to this group significantly reduces potency. Furthermore, to assess if the in vivo metabolites of the biphenyl amides were active against PAl-1, structurally inspired metabolites were tested and found to yield no activity.

Included in

Chemistry Commons

Share

COinS